OncoMatch/Clinical Trials/NCT05742607
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Is NCT05742607 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies IPH5201 + durvalumab + standard chemotherapy for non small cell lung cancer.
Treatment: IPH5201 + durvalumab + standard chemotherapy — The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Provision of tumor samples ... to confirm Programmed Death-Ligand 1 status
Excluded: EGFR sensitizing mutation
Participants with sensitising EGFR mutations ... [excluded]
Excluded: ALK fusion
Participants with ... ALK translocations [excluded]
Disease stage
Required: Stage IIA, IIB, IIIA
Performance status
WHO/ECOG 0–1
WHO Performance Status or Eastern Cooperative Oncology Group of 0 or 1
Prior therapy
Cannot have received: immune-mediated therapy
Prior exposure to immune-mediated therapy
Cannot have received: chemotherapy
Any medical contraindication to treatment with chemotherapy as listed in the local labelling
Cannot have received: radiation therapy
Patients who have preoperative radiotherapy treatment as part of their care plan
Cannot have received: investigational product
Participation in another clinical study with an investigational product administered within 30 days prior to enrolment
Cannot have received: durvalumab (durvalumab)
Previous study drugs (durvalumab, IPH5201) assignment in the present study
Cannot have received: IPH5201 (IPH5201)
Previous study drugs (durvalumab, IPH5201) assignment in the present study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- St. Anthony's Hospital - BayCare Health System · St. Petersburg, Florida
- H. Lee Moffitt Cancer Center & Research Institute · Tampa, Florida
- University of Chicago Medical Center · Chicago, Illinois
- Northwell Health Cancer Institute / Center for Novel Cancer Therapeutics · Lake Success, New York
- Millennium Research & Clinical Development · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05742607 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Are patients with EGFR alterations eligible?
No. EGFR sensitizing mutation is an exclusion criterion.
Are patients with ALK alterations eligible?
No. ALK fusion is an exclusion criterion.
What disease stage is eligible?
Stage IIA or IIB or IIIA is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify